Moreover, PCSK9 inhibitors such as alirocumab and evolocumab promote LDL-C clearance by blocking PCSK9 function, thereby ameliorating CVDs such as AS and angina [189, 190]. This evidence concerns the gene PCSK9 and angina pectoris.